The persistence of controversy surrounding iNO in the neonatal intensive care of premature infants derives from contrasting clinical trial data and divergent professional guidelines. Historically, consensus statements from authoritative bodies such as the National Institutes of Health (NIH) and the American Academy of Pediatrics have generally recommended against iNO therapy in preterm infants, cautioning clinicians due to a lack of robust evidence supporting efficacy and concerns about safety. These guidelines predominantly reflect trials that judged PH severity and treatment response using indirect clinical parameters such as oxygenation index and respiratory distress scores, rather than direct, standardized echocardiographic evaluations of pulmonary arterial pressure (PAP) and pulmonary vascular resistance.

More recent clinical observations and registry data have suggested that iNO might be beneficial in carefully selected subsets of preterm infants with pulmonary arterial hypertension, especially when resistance-mediated PH is precisely diagnosed through comprehensive echocardiographic techniques, showcasing measurable reductions in pulmonary artery pressures and improvements in oxygenation during the transitional physiology period after birth. Prospective cohort studies have underscored this possibility, demonstrating notable responsiveness to iNO in infants as immature as 22 weeks gestation. Thus, while the recent RCT found no statistically significant differences in BPD or mortality outcomes, the discordance between real-world clinical experience and controlled trial data necessitates deeper analysis into the study design and population characteristics.

One major limitation of the trial is its reliance on echocardiographic criteria alone to evaluate PH severity and iNO treatment response, without integration of oxygenation parameters reflective of clinical status. Interestingly, infants enrolled in the trial were required to have a fractional inspired oxygen (FiO2) below 30%, a relatively low oxygen requirement inconsistent with typical clinical indications for initiating iNO. This low baseline FiO2 could have constrained the capacity to detect meaningful improvements in oxygenation following iNO administration, thus potentially underestimating the therapeutic effect. Furthermore, the trial excluded infants who had received iNO for HRF before enrollment—precisely those with more severe disease who might derive the most benefit from treatment. Such stringent inclusion criteria essentially limit generalizability and may mask the true impact of iNO in higher-risk populations characterized by severe PH.

Cardiovascular physiology during neonatal transition is complex and dynamic, and the trial’s approach to PH assessment did not reflect this known variability. Parameters such as patent ductus arteriosus (PDA) gradient, maximum tricuspid regurgitation velocity (TRVmax), and septal flattening were obtained to estimate PAP, yet the trial did not rigorously characterize different PH phenotypes—namely resistance-mediated, flow-mediated, or post-capillary PH. These distinctions are critical, because each phenotype involves distinct pathophysiology and differing responses to vasodilator therapy such as iNO. The assumption of a static PH phenotype over time ignored potential hemodynamic shifts during the neonatal course, including transitions from resistance-mediated to flow-mediated PH. This oversight could obscure understanding of iNO responsiveness and risks inadvertently prolonging treatment when weaning is clinically indicated, with potential adverse effects such as increased risk of intraventricular hemorrhage secondary to reperfusion injury or systemic hypoperfusion.

Critically, the therapeutic monitoring protocols within the trial did not employ multiparametric targeted neonatal echocardiography, which current consensus guidelines endorse to achieve precision in diagnosing PH subtypes and tailoring interventions. Incorporating comprehensive echocardiographic assessment combining qualitative and quantitative data, including function of both ventricles, loading conditions, shunt dynamics, and pulmonary arterial pressures, offers a nuanced understanding that could optimize iNO dosing, timing, and duration. This is paramount in premature infants, whose cardiopulmonary physiology can rapidly evolve.

The trial also highlighted the limited data defining the optimal dosing and weaning strategies for iNO in premature infants with resistance-mediated PH. This is a crucial knowledge gap, as iNO dose and exposure duration appear to modulate therapeutic outcomes. Some neonatal intensive care units have adopted protocols involving lower initial doses of iNO accompanied by meticulous monitoring of hemodynamic and respiratory parameters, allowing for personalized weaning schedules. This approach may mitigate adverse events and maximize benefit but was not explored or accounted for in the recent trial, potentially influencing the overall findings.

Another confounding variable insufficiently addressed in the study is the role of PDA physiology, which significantly influences pulmonary hemodynamics in premature infants. The study did not assess how ductal size, shunt directionality, and temporal changes affected PH evaluation and response to iNO. Ductal closure and left-to-right shunting alter pulmonary blood flow and pressure, complicating the attribution of changes in PAP solely to intrinsic pulmonary vascular tone. Overlooking these nuances risks misclassification of PH severity and therapeutic response, impairing both trial outcomes and clinical decision-making.

Given these considerations, the premature termination of the trial and its null findings regarding the utility of iNO in treating early PH in extremely premature infants with low oxygen needs should be interpreted with caution. The study’s design choices limit its applicability, failing to capture the spectrum and dynamism of pulmonary vascular disease in this fragile population. Consequently, the results do not justify wholesale abandonment of iNO therapy in neonates with echocardiographically confirmed PH, especially those demonstrating clinical signs of significant pulmonary vascular compromise.

Moving forward, future investigations must integrate comprehensive echocardiographic phenotyping with serial assessments to elucidate the complex interplay of pulmonary vascular resistance, cardiac function, and shunt physiology. Trials incorporating variable dosing regimens and stratification by PH subtype alongside rigorous safety monitoring can better define which subpopulations of premature infants stand to benefit most from iNO therapy. The precision medicine approach incorporating multiparametric echocardiographic tools and individualized treatment algorithms represents the frontier for optimizing outcomes in neonatal pulmonary hypertension.

In conclusion, this recent RCT contributes valuable data to the ongoing dialogue surrounding iNO use in extremely premature infants but is constrained by significant methodological limitations that temper its conclusions. Neonatologists must continue to employ a detailed, physiology-based approach when assessing pulmonary hypertension and considering iNO therapy rather than relying solely on simplified clinical trial outcomes. As the understanding of neonatal PH pathophysiology deepens and echocardiographic technology advances, tailored therapeutic interventions hold promise for improving both survival and long-term respiratory outcomes for the most vulnerable infants.

Subject of Research:
Efficacy of inhaled nitric oxide therapy in the treatment of pulmonary hypertension among extremely premature infants.

Article Title:
Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes?

Article References:
King, T.L., McNamara, P.J. & Bischoff, A.R. Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes?. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02666-1

Image Credits:
AI Generated

DOI:
09 April 2026

The meta-analysis synthesized data from sixteen randomized controlled trials encompassing a cohort of 500 preterm infants, thereby achieving a robust sample size for statistical validation. The investigators focused primarily on the response to heel lance, a common but painful diagnostic procedure performed on neonates. By measuring indicators of pain such as heart rate (HR), oxygen saturation (SpO₂), and behavioral pain scales at 30 seconds post-procedure, the study determined the effectiveness of a 25% concentration oral glucose solution in comparison to breast milk and placebo.

Remarkably, the 25% oral glucose solution demonstrated a significant reduction in pain scores relative to breast milk, a widely employed natural analgesic in neonatal practice. This finding challenges the conventional reliance on breast milk alone as an effective intervention and suggests that glucose at a specific concentration can offer superior analgesic benefits. The magnitude of pain reduction observed implies that glucose administration induces rapid endogenous opiate release or stimulates sensory pathways that modulate nociceptive input, although the precise neurochemical mechanisms remain under investigation.

In addition to behavioral pain assessments, physiological parameters were closely scrutinized. Contrary to expectations, no statistically significant differences in HR or SpO₂ were noted when comparing glucose to breast milk, suggesting that both interventions similarly stabilize cardiorespiratory function during painful stimuli. However, when oral glucose was compared to placebo controls, a clear physiological benefit emerged. Infants receiving 25% glucose exhibited significantly lower HR and improved SpO₂ levels, denoting enhanced autonomic regulation and oxygenation. These findings validate the inclusion of glucose as a frontline analgesic in procedural pain management protocols where standard care may be insufficient.

The methodological rigor of this meta-analysis is notable; the authors applied inverse-variance fixed effects modeling to continuous data, ensuring that the pooled effect size estimates were reliable and reproducible. Risk of bias was meticulously assessed using the RoB 2.0 tool, while the GRADE approach provided transparency regarding the certainty of evidence. This dual-layered quality appraisal strengthens confidence in the conclusions drawn and highlights the clinical relevance of oral glucose for premature infant pain mitigation.

An important consideration raised by the study is dosage optimization. The evidence converges around 25% glucose concentration as minimally effective, highlighting the balance between efficacy and safety. Excessive glucose dosage risks hyperglycemia and metabolic disturbances in vulnerable neonates, whereas subtherapeutic concentrations may fail to provide adequate analgesia. The findings support the establishment of standardized dosing regimens tailored to gestational age and procedural pain intensity to maximize therapeutic benefits without compromising neonatal homeostasis.

Moreover, the researchers emphasize the non-invasive nature of oral glucose administration as a critical advantage. It offers a practical and swift solution amenable to bedside use without the logistical or pharmacodynamic complexities often associated with pharmacological analgesics. This feature is pivotal in busy neonatal intensive care units, where timely pain relief can mitigate the long-term neurodevelopmental consequences of repeated nociceptive stress.

Building upon previous smaller-scale studies, this meta-analysis consolidates the clinical literature into a coherent framework, paving the way for guideline updates and training initiatives. Neonatal practitioners are urged to incorporate oral glucose into routine pain management protocols for invasive procedures, particularly heel lancing, to enhance infant comfort and potentially improve developmental outcomes by minimizing procedural stress.

Additionally, the study underscores the necessity for further research into the mechanistic action of glucose as an analgesic agent in neonates. Investigations into opioid receptor involvement, glucose-induced neurotransmitter modulation, and the interplay with endogenous analgesic pathways could refine pharmacological strategies and improve therapeutic precision. Understanding these biochemical mechanisms may also elucidate differential responses based on neonatal maturity and individual variability.

Despite the encouraging results, the authors caution that glucose administration should complement, not replace, comprehensive pain management approaches encompassing environmental modifications, non-nutritive sucking, swaddling, and parental involvement. The multimodal framework is essential to holistically address the multifaceted nature of neonatal pain perception and behavioral response.

Safety endpoints were reassuringly favorable, with no significant adverse effects linked to oral glucose observed across the assembled trials. This positions glucose as a viable option in neonatal settings where safety concerns often limit pharmacotherapy. Continuous monitoring and long-term follow-up studies are recommended to detect any latent metabolic or developmental sequelae.

In the broader context of neonatal analgesia, these findings catalyze a paradigm shift towards safe, effective, and evidence-based pain mitigation strategies. They emphasize the ethical imperative to alleviate neonatal suffering using low-risk interventions supported by rigorous scientific evaluation, aligning with contemporary patient-centered care models.

As neonatal survival rates improve globally, emphasis on quality of life, including pain management, becomes paramount. This meta-analysis marks a significant advance, establishing oral glucose as a cornerstone of procedural pain relief with the potential to become a universally adopted practice.

Ultimately, the integration of oral glucose into clinical protocols offers a tangible avenue to reduce the burden of pain in the most fragile human patients. The study acts as a compelling call to action for neonatal care providers to harness this simple yet powerful analgesic tool, thereby transforming neonatal pain management paradigms and improving the early life experience of premature infants.

Subject of Research: Effectiveness and safety of oral glucose for pain relief during invasive procedures in premature infants.

Article Title: Effect of glucose on pain relief during invasive procedures in premature infants: Systematic review and meta-analysis of randomized controlled trials.

Article References:
de Souza, A.T.B., da Câmara Dantas, H.G., de Oliveira, D.J.D. et al. Effect of glucose on pain relief during invasive procedures in premature infants: Systematic review and meta-analysis of randomized controlled trials. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02448-1

Image Credits: AI Generated

DOI: 05 November 2025

Therapeutic hypothermia operates on the principle of mitigating secondary brain injury after an initial hypoxic-ischemic insult by lowering core body temperature, thereby reducing cerebral metabolic rate, attenuating excitotoxicity, and modulating inflammatory cascades. While its efficacy in term neonates is well established through robust randomized controlled trials (RCTs) and meta-analyses, late preterm infants have historically been excluded from such trials due to concerns about their increased physiological vulnerability and developmental immaturity. The crux of the controversy lies in whether the neuroprotective benefits seen in term infants translate effectively—and safely—to those born in the late preterm window.

Preclinical animal studies provide important mechanistic insights by simulating brain injury at developmental stages comparable to human late preterm infants. These models consistently demonstrate that TH confers neuroprotection even at these earlier maturational stages, reducing inflammation, limiting neuronal apoptosis, and preserving white matter integrity. Such findings suggest a compelling biological rationale for cautiously considering TH in late preterm neonates who suffer from HIE. However, laboratory success does not always equate to clinical efficacy, and neonates in this GA bracket exhibit marked differences in organ system maturity, metabolism, and thermoregulatory capacity that may influence both the safety and effectiveness of TH.

Moving from bench to bedside, retrospective cohort studies and registry data have explored the feasibility and outcomes of applying TH to late preterm infants. These studies reveal a heterogeneous clinical landscape, with some centers reporting successful implementation of TH protocols and others documenting increased rates of adverse events such as coagulopathy, hypotension, and metabolic instability—complications that may be exacerbated by the physiological fragility of infants at 34 weeks’ GA or younger. Notably, retrospective analyses often suffer from selection bias, incomplete data, and variable treatment protocols, limiting their capacity to provide definitive guidance on practice.

The pivotal clinical evidence comes from the only randomized controlled trial specifically enrolling infants at 33 to 35 weeks’ GA with moderate to severe HIE, which paradoxically failed to demonstrate a neuroprotective benefit of TH in this group. Even more concerning, it suggested potential harm in treated infants, including heightened mortality and morbidity. Such results have led to a hesitant and circumspect approach toward TH in late preterm infants, with many clinicians reluctant to initiate cooling outside of specialized centers or research protocols. Yet, a critical examination of the trial reveals significant limitations that temper the conclusiveness of its findings.

First, baseline imbalances between treatment groups—such as differences in the severity of encephalopathy and other demographic variables—confound the interpretation of outcomes. Second, the trial lacked adequate stratification by gestational age and encephalopathy severity, variables that are crucial for understanding differential responses to TH in a heterogenous late preterm cohort. Third, the absence of detailed neuroimaging and electroencephalographic (EEG) assessments weakens the ability to precisely characterize injury patterns and neurological outcomes, which could inform patient selection and therapeutic targeting. Consequently, while the trial raises important safety concerns, it does not categorically rule out potential benefits in carefully selected late preterm neonates.

Real-world clinical practice appears to echo this ambiguity. An international survey including 88 NICUs revealed that despite the lack of unequivocal evidence supporting TH in infants born between 34 and 35 weeks’ GA, many centers continue to employ hypothermia treatment protocols. These practices vary not only by geographical region and institutional culture but also depend on individual patient characteristics and clinician experience. Intriguingly, data aggregated from 22 centers demonstrate lower mortality rates than those reported in the RCT, hinting that real-world outcomes may differ from controlled trial environments, possibly due to differences in patient selection, supportive care, or protocol nuances.

The collective evidence underscores that while TH remains a viable and potentially beneficial intervention for select infants born at 35 weeks’ GA experiencing moderate to severe HIE, its indiscriminate use in neonates born at 34 weeks or earlier warrants caution. The increased risk profile and uncertain benefit demand that routine therapeutic hypothermia in these younger preterm infants be confined to research settings where rigorous monitoring, standardized neurological assessment, and comprehensive data collection are ensured.

Looking forward, it is imperative that future investigations adopt nuanced, stratified study designs that recognize the developmental heterogeneity within the late preterm population. Implementing standardized neurological evaluation frameworks, including advanced neuroimaging and continuous EEG, will be essential to delineate which infants derive measurable benefit from TH and to identify potential biomarkers predictive of outcomes. Such data will facilitate the tailoring of cooling protocols—perhaps adjusted for gestational age and injury severity—and optimize the risk-benefit ratio.

Moreover, integrating translational science with clinical research can elucidate mechanistic pathways that underlie differential responses to hypothermia across developmental stages, potentially identifying adjunctive therapies or novel neuroprotectants tailored to late preterm physiology. Understanding the interplay of systemic immaturity, cerebral vulnerability, and TH-induced physiological perturbations will be central to refining clinical guidelines and ensuring equitable neonatal neuroprotection.

This evolving discourse exemplifies the challenges inherent to extending established therapies beyond initially studied populations, highlighting the necessity of bridging rigorous scientific inquiry with pragmatic clinical judgment. As neonatal intensive care units around the world grapple with these complex decisions, a balanced approach grounded in evidence, ongoing surveillance, and multidisciplinary collaboration will be pivotal.

In summary, therapeutic hypothermia remains a cornerstone of care for term infants with hypoxic-ischemic encephalopathy, but when it comes to late preterm neonates between 33 and 35 weeks’ gestation, the therapeutic window narrows significantly. The current landscape is characterized by encouraging preclinical data, inconclusive and sometimes conflicting clinical trial results, and diverse real-world practices that together underscore an urgent need for further robust research. Until such data emerge, cautious, individualized application of TH in this delicate group, predominantly within structured research frameworks, is the most prudent path forward.

The ongoing pursuit to optimize neurodevelopmental outcomes in late preterm infants with hypoxic-ischemic brain injury exemplifies the frontier of neonatal medicine—where cutting-edge therapies must be judiciously calibrated against intricate developmental biology and the mandates of patient safety. El-Dib and colleagues’ synthesis provides a vital compass as clinicians and researchers navigate this complex clinical terrain, signaling both the promise and perils of therapeutic hypothermia in the late preterm population.

Subject of Research: Therapeutic hypothermia for hypoxic-ischemic encephalopathy in late preterm infants

Article Title: Benefits and risks of therapeutic hypothermia for hypoxic-ischemic encephalopathy in late preterm infants

Article References: El-Dib, M., Abdelgadir, D., Ahmad, K.A. et al. Benefits and risks of therapeutic hypothermia for hypoxic-ischemic encephalopathy in late preterm infants. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04428-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04428-9